InvestSMART

AdAlta Limited (ASX: 1AD) - Announcements

- Current share price for 1AD : $0.004

ASX company news and announcements for AdAlta Limited (1AD) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All AdAlta Limited (1AD) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than AdAlta Limited (1AD), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for AdAlta Limited (1AD)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$13 Investor presentation including future milestones 30 Jul 2020 8:47AM $0.125 $0.004 fallen by 96.80%
$13 AdAlta to present at IRD Invest virtual conference 24 Jul 2020 8:34AM $0.130 $0.004 fallen by 96.92%
$13 First participants treated in AD-214 Phase I trial 23 Jul 2020 2:21PM $0.100 $0.004 fallen by 96%
$13 Initial Director's Interest Notice 22 Jul 2020 9:37AM $0.097 $0.004 fallen by 95.88%
$13 David Fuller appointed as non-executive director 22 Jul 2020 8:37AM $0.097 $0.004 fallen by 95.88%
$13 Quarterly Appendix 4C and Activities Report 21 Jul 2020 8:58AM $0.092 $0.004 fallen by 95.65%
$13 Supportive US FDA pre-IND meeting results for AD-214 20 Jul 2020 8:20AM $0.100 $0.004 fallen by 96%
$13 AdAlta to present at TechKnow Invest Webinar 15 Jun 2020 4:46PM $0.098 $0.004 fallen by 95.92%
$13 AdAlta receives approval to commence AD-214 Phase I trial 10 Jun 2020 8:52AM $0.081 $0.004 fallen by 95.06%
$13 BIO Presentation 5 Jun 2020 8:21AM $0.073 $0.004 fallen by 94.52%
$13 Investor Presentation 30 Apr 2020 4:40PM $0.061 $0.004 fallen by 93.44%
$13 Quarterly Appendix 4C and Activities Report 29 Apr 2020 8:54AM $0.060 $0.004 fallen by 93.33%
$13 Business update and COVID-19 response 31 Mar 2020 9:32AM $0.055 $0.004 fallen by 92.73%
$13 Final Director's Interest Notice x 2 30 Mar 2020 5:10PM $0.055 $0.004 fallen by 92.73%
$13 Board changes and R&D Tax Incentive advance received 27 Mar 2020 9:05AM $0.041 $0.004 fallen by 90.24%
$13 Issuance and cancellation of options 23 Mar 2020 8:26AM $0.057 $0.004 fallen by 92.98%
$13 Appendix 3G 23 Mar 2020 8:24AM $0.057 $0.004 fallen by 92.98%
$13 CXCR4 in fibrosis publication 10 Mar 2020 8:28AM $0.070 $0.004 fallen by 94.29%
$13 Change of Director's Interest Notice 10 Mar 2020 8:28AM $0.070 $0.004 fallen by 94.29%
$13 Investor Briefing - Strategic Plan 3 Mar 2020 9:32AM $0.076 $0.004 fallen by 94.74%
$13 AD-214 PK and PD support Phase I weekly dosing objective 2 Mar 2020 12:17PM $0.072 $0.004 fallen by 94.44%
$13 AD-214 effective in gold standard pre-clinical animal model 2 Mar 2020 8:45AM $0.080 $0.004 fallen by 95%
$13 Half Yearly Report and Accounts 26 Feb 2020 7:02PM $0.080 $0.004 fallen by 95%
$13 Investor strategy briefing scheduled 17 Feb 2020 8:27AM $0.088 $0.004 fallen by 95.45%
$13 AdAlta updated corporate presentation 10 Feb 2020 8:23AM $0.100 $0.004 fallen by 96%

501 - 525 of 750 results

Page 21 of 30

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.